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A B S T R A C T
The number of transplant recipients with tropical infectious diseases is growing due to increasing
international travel and the rising number of transplants taking place in the tropics and subtropics. With
increases in population migration, the prevalence of individuals infected with geographically restricted
organisms also rises. There are three potential categories of tropical infections in transplant patients: (1)
donor-related infections transmitted by the graft or through transfusion of blood products; (2)
reactivation or recrudescence of latent infections in the donor recipient; and (3) de novo acquisition of
infection in the post-transplant period through the traditional route of infection. We present an overall
discussion of the association of parasitic (protozoa and helminths) and non-parasitic (viral, bacterial, and
fungal) tropical infectious diseases and solid-organ and hematopoietic transplantation. We also suggest
potential screening guidelines for some of these tropical infections.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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More transplantation procedures are being performed annually,
resulting in an increase in the number of immunocompromised
hosts.1–7 Most of the literature in infectious diseases in transplanta-
tion has focused on common pathogens prevalent in industrialized
Westerncountries,wheremost transplantationsurgeriesoccur.1,2,4–
7However, in the lastdecade, therehasbeenagrowing identiﬁcation
of tropical infectious diseases occurring in transplant hosts in
endemic and non-endemic settings.3,4,7–11 The epidemiologic
reasons for the growing number of reports of tropical infections
appearing in transplant recipients include: (1) increasing travel of
transplanted patients to the tropics and subtropics;8,12,13 (2)
increasing population immigration from endemic areas for tropical
infections to non-endemic settings;6,14,15 (3) increasing numbers of
transplantation procedures taking place in tropical countries;11,16–
19 and (4) many individuals traveling overseas for ‘transplant
tourism’ in countries with high prevalence of tropical infectious
diseases.20,21 In general, transmission of these infections occurs
through three main routes: donor-derived infections,3,4,6,15,22
reactivation or recrudescence of latent infections,16,22–24 or trans-* Corresponding author. Tel.: +1 404 686 5885; fax: +1 404 686 4508.
E-mail address: cfranco@sph.emory.edu (C. Franco-Paredes).
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doi:10.1016/j.ijid.2009.04.021mission de novo during the post-transplant period.4,16 Infectious
pathogens may be carried by the graft or the infection may be
acquired through transfusion of blood products during or after the
transplantation.3,4,6,16,25–29
Post-transplantation tropical infections are not considered by
most clinicians and therefore are frequently misdiagnosed.6,22,30–36
Reactivation (recrudescence) in the organ recipient of latent or
dormant infections is a frequent source of tropical infections.4,6,22,25
Examples of this mechanism include infection with Strongyloides
stercoralis leading to disseminated strongyloidiasis35 or hyperinfec-
tion syndrome25,29,35 and Trypanosoma cruzi, leading to increased
replication of parasites that produces symptoms similar to those
seen during the acute stages of Chagas disease.6,16,22 New infections
in the post-transplantation period are a common source of tropical
acquired infections in travelers and people residing in endemic
areas.8,19,29 In other cases of tropical parasitic infections such as
alveolar echinococcosis caused by Echinococcus multilocularis, liver
transplantation has been attempted as a salvage therapeutic
alternative with variable success among those individuals not
responding to other surgical and medical interventions.37,38 In a
similar, manner heart transplantation has been adopted as salvage
therapy for patients with Chagas cardiomyopathy.39–41
There is an increasing number of transplant recipients traveling
to the tropics and acquiring malaria, dengue, and other tropical
infections.8,13,30 The risk of acquiring tropical infections afterses. Published by Elsevier Ltd. All rights reserved.
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in endemic areas.4,13,30 A recent survey demonstrated that 29% of
heart transplant recipients traveled to resource-constrained
countries within a year of transplantation.30 The risk of becoming
infected with tropical infectious diseases will vary by destination,
type of exposures, purpose of the trip, level of accommodation,
hygiene and sanitation level, and the behavior of the transplant
traveler.8,12 A study from Toronto showed that 36% of transplant
patients traveled internationally, and of these, 50% traveled to
malaria and dengue endemic areas. Interestingly, only 67% sought
pretravel advice from a specialist other than a travel medicine
expert and only 25% adhered to malaria prevention strategies.13
There is evidence that tropical infectious diseases may negatively
impact the course of transplantation since the diagnosis and
treatment of these infections may be altered or more difﬁcult;
additionally, an increased pathogen burden may augment
morbidity and mortality.1–6,29,31–34 In addition, reports suggest
that some tropical infectious diseases may increase the risk of
transplant rejection.4 Thus, it is imperative to encourage transplant
recipients traveling to high-risk areas to seek pretravel expert
advice in order to minimize their risk of acquiring tropical
infections through preventive strategies and vaccines.8,12
The purpose of this review is to present a general overview of
key tropical infectious diseases (parasitic, viral, bacterial, and
fungal) that are increasingly identiﬁed in transplant recipients. We
also brieﬂy discuss some infectious pathogens occurring in
transplant recipients that are traditionally considered tropical
infections but that are also transmitted – albeit less frequently - in
non-tropical settings. We searched PubMed with the keywords
transplantation, tropical infections, and specifying particular
pathogens (viral, bacterial, fungal, and parasitic) and matching
them to keywords ‘transplant’ or ‘transplantation’. We also cross-
referenced among the different sections and topics. We reviewed
250 references; only 135 of themost relevant references chosen by
disease frequency and clinical impact among transplant recipients
have been included in this review.
2. Tropical parasitic infections (protozoa and helminths) in
transplant recipients
The main parasitic diseases reported in organ transplant
recipients are caused by protozoa, although an increasing number
of nematode infections have been reported recently.4,19,27–29,42–44
This may be due to the fact that pathogenic protozoa have the
ability to replicate in the host as in cryptosporidiosis, microspor-
idiosis, and other protozoa, and this ability is not possessed by
most helminths.4,9,45–48 Toxoplasmosis has been considered one of
the most frequent protozoal infections in transplant recipients but
most reports come from non-tropical industrialized areas of the
world.1–5,49 However, as solid-organ transplantations, particularly
renal transplants, are becoming a therapeutic option in different
tropical settings in the world, a new trend of complications related
to tropical parasitic infectious diseases is appearing.4,29,29,50
Indeed, there has been an increasing number of reports of
strongyloidiasis and Chagas disease occurring in transplant
recipients not only in immigrants to non-endemic settings, but
also appearing in endemic settings.16,19,29
2.1. Helminthic infections and transplantation
2.1.1. Strongyloidiasis and transplantation
In the life cycle of S. stercoralis, a helminthic infection that
affects 30 to 50 million worldwide, some rhabditiform larvae
transform into the invasive ﬁlariform larvae before being excreted
in human stools.25,35,51 In this autoinfection cycle, larvae penetrate
the intestinal mucosa or perianal skin and then migrate to thedeﬁnite site in the small intestine and are therefore capable of
chronically re-infecting the host.35 Strongyloides hyperinfection
syndrome is an acceleration of autoinfection generally occurring
among immunosuppressed individuals.51 Disseminated strongy-
loidiasis refers to infections in which larvae are found beyond the
range of the pulmonary autoinfective life cycle such as in the
brain.35,51 Strongyloides hyperinfection syndrome or disseminated
strongyloidiasis are frequently misdiagnosed in transplant reci-
pients due to the low clinical suspicion and since eosinophilia is
absent in many cases.25,36 Many cases of hyperinfection have been
associated with the use of high dose steroids and other
immunosuppressive agents during episodes of rejection or graft-
versus-host disease, usually within the ﬁrst three months post-
transplantation.4,25,35,36,51 Potential reasons for corticosteroids
resulting in hyperinfection syndrome include: (1) direct effect on
the parasite by accelerating the transformation to ﬁlariform larvae;
(2) direct effect on the parasite by rejuvenating reproductively
latent adult females; and (3) direct effect on the immune systemby
suppressing eosinophilia and lymphocyte activation.51
Strongyloides hyperinfection has a mortality exceeding 80% and
eradication of this nematode in the form of symptomatic or
asymptomatic uncomplicated infection prior to transplantation
has been reported to improve transplantation outcomes.1–4,28,29
Cadaveric donors have been responsible for some transplant-
associated cases of strongyloidiasis.29 In some settings, screening of
cadaveric donors for Strongyloides is mandatory before accepting
them for donation, and prophylaxis is required for all recipients.4,29
No case of hyperinfection syndrome has been reported in solid-
organ transplant recipients receiving cyclosporine.1–4,52,53 These
clinical observations have been supported by animal models
showing the antiparasitic activity of cyclosporine.52,53
Management of disseminated Strongyloides infection in
transplant patients is challenging because patients are usually
severely ill and unable to take oralmedications.35,43 Ivermectin can
be administered by the oral, subcutaneous, or the rectal route.12,13
Alternatively, albendazole has also been recommended at 400 mg
PO twice daily for two days (10 days for hyperinfection syndrome
or disseminated disease).43 The use of pre-emptive therapy during
episodes of acute rejection among those transplant recipients
previously diagnosed and treated for strongyloidiasis has also been
suggested.4,43
2.1.2. Neurocysticercosis and transplantation
Cases of neurocysticercosis occurring in transplant recipients
are uncommon and mostly reported with renal transplanta-
tion.1,2,42,44 However, when reported in the literature, Taenia
solium infection may be more likely to result in multiple-organ
involvement. In addition, worsening neurological symptoms and
ﬁndings consistent with neurocysticercosis requiring antiparasitic
therapy have also been described in a few liver transplant
recipients early after transplantation with commencement of
immunosuppressive therapy regimens.42,44 Therefore, neurocys-
ticercosis should be kept in the differential diagnosis of central
nervous system ring enhancing lesions when occurring in
transplant recipients along with toxoplasmosis, post-transplanta-
tion lymphoproliferative disease, tuberculomas, and meningoen-
cephalitis due to T. cruzi. Treatment requires the use of albendazole
and steroids, similar to cases of neurocysticercosis in non-
transplant recipients.1,2,42,44
2.1.3. Echinococcosis and transplantation
There are no reports so far in the literature of echinococcal
disease due to Echinococcus granulosus acquired de novo in
transplant recipients.37 The larvae of E. multilocularis grow
primarily in the liver of an infected person, developing as an
invasive tumor-like lesion. As a result, in some individuals alveolar
Figure 1. Detection of a trypomastigote of Trypanosoma cruzi in a peripheral blood
smear in a transplant recipient at our institution, acquired from the donor through
the graft.6
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in the use of liver transplantation as salvage therapy.37,38
Combination therapy is recommended for incurable alveolar
echinococcosis and includes antiparasitic chemotherapy, inter-
ventional therapy, and radical surgery. While there is a signiﬁcant
risk of proliferation of intraoperatively undetected parasitic
remnants, some centers in highly endemic areas have shown that
liver transplant is a feasible strategy in incurable alveolar
echinococcosis.38
2.1.4. Filariasis and transplantation
Potential mechanisms of transmission of Wuchereria bancrofti
microﬁlariae include the transplacental route, blood transfusion,
and more recently renal transplantation. These events may be
explained by the presence of microﬁlariae of W. bancrofti residing
inside the capillaries of the lungs, kidneys, and heart and therefore
acquired through blood transfusion or grafts.4,54 The exact
incidence, prevalence, and clinical consequences of this parasitic
infection in transplant recipients remains to be elucidated in
association with the increasing number of transplantations taking
place in endemic areas.55
2.2. Protozoal infections and transplantation
2.2.1. Trypanosoma cruzi and transplantation
As the trend for global migration increases, Chagas disease is
expanding from rural to urban areas and endemic to non-endemic
areas.6,15,22 As a result, cases of Chagas disease have been described
in many areas of the world with many of these cases occurring due
to reactivation of latent infection in immunosuppressed indivi-
duals, such as the HIV-infected and transplant recipients.6,22 In this
manner, the majority of infected persons with Chagas disease are
asymptomatic, and their disease remains latent and undiagnosed
before it reactivates (from the donated organ or in a previously
infected host) due to immunosuppression in transplant recipients
or transmitted through blood transfusion.6,22
In transplant recipients, reactivation of T. cruzi infection may
produce myocarditis, meningoencephalitis, and dermatologic
lesions associated to the use of high dose corticoster-
oids.1,2,6,22,56–66 Clinically, cutaneous Chagas disease may produce
indurated erythematous plaques with necrosis, erythematous
papules and nodules, panniculitis, or skin ulcerations.56,57
Transmission of T. cruzi infection by solid-organ transplantation
(particularly renal transplants) has been reported in Latin
America.6,22 In the USA, transmission of T. cruzi through solid-
organ transplantation has also been reported. In our institution, we
previously experienced two cases of acute Chagas disease in two
solid-organ transplant recipients associated with a single donor in
2001 (Figure 1).6 An additional two cases were reported in Los
Angeles in 2005 in two heart-transplant patients from different
donors.22 The largest reported clinical series of Chagas disease in
kidney transplantations in Argentina screened a total of 238 renal
transplant recipients and donors and prospectively followed them
for evidence of T. cruzi infection.16 This study demonstrated the
increased vulnerability of organ recipients to reactivation of latent
infection; infection was acquired through the graft or de novo
infection in the post-transplant periodwhen transplants took place
in endemic areas.16
Diagnosis of T. cruzi infection in transplant recipients is
performed by using peripheral blood smears (Figure 1), tissue
biopsies to identify amastigotes, hemoculture, and serological
analysis.6,15,22,60,61 Treatment should preferentially be with
benznidazole, but nifurtimox is considered an alternative drug
therapy.6,22 At this point in time it is unclear if there is a need for
chronic suppressive therapy similar to HIV-infected patients with
T. cruzi disease.9From a different transplantation angle, heart transplantation
is considered a therapeutic option for those with end-stage
Chagas cardiomyopathy in some endemic settings.39–41 Currently
recommended immunosuppressive regimens in this situation
use a lower level of immunosuppression to reduce the risk of
reactivation.39–41
2.2.2. Malaria and transplantation
Transmission of malaria through transplantation has been
reported in association with kidney, liver, heart, and bone marrow
transplantation.2,4,67 In liver and kidney transplanted hosts, cases
of Plasmodium falciparum and Plasmodium malariae are unusual,
with only a few cases reported in the literature.2,4,67 However,
relapses of clinical disease has occurred in transplant recipients
with latent infection due to Plasmodium vivax and Plasmodium
ovale. In addition, P. ovale and P. vivax can be transmitted through
liver grafts due to the persistence of hypnozoite forms within
hepatocytes for months or even years.4,67
De novo infection is also a signiﬁcant potential risk for people
living or traveling to endemic areas and therefore malaria
chemoprophylaxis and personal protection measures are impor-
tant for individuals at high-risk of complications.4,8 Patients
receiving immunosuppressant drugs should consider beginning a
malaria chemoprophylactic regimen days or weeks (according to
the area and the drug) before departure in order to monitor and
adjust the potential effect on serum levels of immunosuppressant
drugs (tacrolimus, cyclosporine, or sirolimus).8,12
Acute graft dysfunction can result from the hemodynamic
consequences of P. falciparum infection, but there is no clear
evidence to suggest that infected transplant patients tend to
develop severe malaria.4 Screening of both donor and recipient
with peripheral blood smears to detect asymptomatic parasitemia
and serological analysis should be considered in some cases.4,67
2.2.3. Pathogenic amoebas and transplantation
Infection due to Entamoeba histolytica can occur in transplant
recipients, leading to severe colitis and liver abscesses.68 In
addition, the free-living amoebas such as Acanthamoeba, Naegleria
fowleri, and Balamuthia mandrillaris infections have been reported
to occur in transplant recipients.69–76 Disseminated disease has
been described in patients after solid-organ transplantations,
particularly lung transplantation.68,69,71–76 Several cases of
Acanthamoeba infections have been reported in renal transplant
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corneal graft recipients.74–76 B. mandrillaris meningitis was
conﬁrmed at the time of autopsy of a multivisceral transplant
recipient who died two days after receiving alemtuzumab.75
2.2.4. Schistosomiasis and transplantation
The association of liver and kidney transplantation and
schistosomiasis has been reported in many series, frequently in
endemic schistosomal regions and among immigrants living in
Western countries.1,2,4,17,77–80 Acute schistosomiasis may poten-
tially be transmitted by blood transfusion or organ transplantation
only during the short phase of schistosomulamigration. This mode
of transmission has yet to be reported.4 On the other hand,
transplant recipients can be exposed to new infection if there is
exposure to contaminated water.78,79 In addition, disease in both
kidney and liver transplants certainly remains a possibility since
adult worms might survive for many years.78–80 Immunosuppres-
sion appears to have little effect on the natural history of chronic
persistent infection. For renal transplant recipients, the graft
function and rate of rejection are similar regardless of whether
schistosomiasis is present in the host or in the donor kidney, but
recipients with schistosomiasis require higher doses of cyclos-
porine to achieve target blood levels and have a greater incidence
of urological complications.78–80 For bone marrow transplant
recipients, veno-occlusive disease of the liver is more common in
recipients with a prior history of schistosomiasis.80 If the kidney
recipient has a history of schistosomiasis, there is no difference
between schistosomal and non-schistosomal patients in graft
function and the incidence or frequency of graft rejection.77–80 As
schistosomiasis is very common in many countries where kidney
transplantation is largely dependent on the availability of living-
related donors, the viability of using a live kidney donor with
schistosomiasis arises.4,49 Uncomplicated schistosomiasis of living
kidney donors does not adversely affect either the function or the
morphology of the remaining kidney.4
2.2.5. Leishmaniasis and transplantation
Cutaneous or visceral leishmaniasis can be transmitted by the
bite of a female sandﬂyandbyother routessuchas intravenousdrug
useorduringsolid-organorbonemarrowtransplantation.32–33,81–83
In transplant recipients there are some cases of cutaneous disease
and more than 40 cases of visceral leishmaniasis.81–83 In transplant
recipients, Leishmania infection may occur as a reactivation of a
previouslyacquired infection,or itmaybetransmittedfromthegraft
oracquiredafter transplantation.81–83 Inaseriesofelevencases from
France, visceral leishmaniasis was most commonly associated with
renal transplantation, followed by cases among liver transplant
recipients.33 Visceral leishmaniasis is an uncommon condition in
bonemarrow transplant recipientswith only a few cases reported in
the literature and some of these cases acquired from the
donor.32,33,81,83 Most reported cases of visceral leishmaniasis in
transplantrecipientshaverequired long-termsuppressive therapy
similar to patients co-infected with HIV/AIDS.1,2,9,33
3. Tropical non-parasitic infections (viral, bacterial, and
fungal) and transplantation
3.1. Viral infections and transplantation
Many transplanted patients may live or travel to regions where
some of the most frequent viral tropical infections are prevalent.
Transplant recipients traveling to resource-constrained settings
endemic for tropical infections including yellow fever, dengue,
rabies, and other viral pathogens should seek expert pretravel
medical advice to maximally decrease their risk of infection.8,12
This is important as immunosuppression associated with trans-plantation may affect the outcome of acute viral infections or the
course of virus latency, with potential life-threatening conse-
quences.84 There are reports of HIV,11,20,21 hepatitis B,11,20,21
hepatitis C,20-21 measles,85,86 human T-lymphotropic virus type 1
(HTLV-1) infection,87–89 dengue,90–92 and other viral pathogens
being responsible for signiﬁcant sequelae and mortality in
transplant recipients.93 In this regard, yellow fever presents a risk
to transplant recipients who are traveling to endemic areas in part
because the vaccine is live and therefore should be avoided.8,12
Transplant tourism has been responsible for a signiﬁcant number
of patients acquiring hepatitis B, hepatitis C, or HIV-infection in
those transplanted overseas.11,20,21,93 There may also be an
increased risk of West Nile virus infection, lymphocytic chorio-
meningitis virus, or some hemorrhagic fever virus inmany tropical
areas of the world, including some parts of the Indian subconti-
nent, sub-Saharan Africa, and Latin America, but there are only
recent descriptions, mostly in non-tropical settings.94–102 It
remains to be determined if other similar ﬂaviviruses such as
Japanese encephalitis virus may pose an increased risk of
complications in transplant recipients.103 Rabies is rarely observed
after transplantation with only a few cases acquired from infected
donors in industrialized countries.3,104,105 However, with increas-
ing travel of transplant recipients to areas where rabies may be
more prevalent and also due to transplant tourism, rabies becomes
a potential pathogen for transplant recipients. In addition, live
rabies vaccine for use in wildlife has caused human disease and
presents a potential risk to transplant recipients who come into
direct contact with wildlife.3 We discuss below, in more detail,
some HTLV-1, measles, and dengue virus infections in transplant
recipients. Although these infections may be acquired in non-
tropical settings, the risk of their acquisition is higher in
developing tropical areas of the world.
3.1.1. HTLV-1 and transplantation
This virus is endemic in parts of southern Japan, the Caribbean,
Africa, and South America. In some of these areas, more than 1% of
the general population is infected, thoughmosthave latent infection
and remain asymptomatic.87–89 However, HTLV-1 can be associated
with multiple diseases including neoplastic (acute T-cell leukemia/
lymphoma), opportunistic infections (strongyloidiasis, Norwegian
scabies, and others), and inﬂammatory complications (HTLV-1-
associated myelopathy-tropical spastic paraparesis).87–89 The virus
is transmitted from mother to child, sexually, and through
transfusion of contaminated blood products.89 The virus is cell-
associated, and transfusion of packed red cells, whole blood,
and platelets, results in seroconversion in more that 40% of
recipients.106,107
Organ transplantation has been identiﬁed as another potential
route of transmission, yet the exact prevalence ofHTLV-1 among the
transplant population is unknown.87,88 In fact, HTLV-1 has been
considered by some transplantation authorities a contraindication
toorgandonationbecauseof the riskof transmissionof infectionand
the subsequent development of either adult T-cell leukemia or
myelopathy.87–89 In some reports, transplant recipients of solid-
organs have developed HTLV-1-associated myelopathy within two
years post-transplantation, raising the question ofwhether all organ
donors and recipients should be screened for HTLV-1.88,89 Currently
available assays have a high level of sensitivity and speciﬁcity to
identify HTLV-1-infected individuals. As in all the other currently
performed donor-screening tests, positive HTLV-1 serologies allow
transplantation physicians to make informed decisions about the
suitability of organ donors.87,89,106,107 Importantly, there is evidence
to indicate that carriers of HTLV-1 who receive transplants and
immunosuppressive drugs thereafter are at an increased risk
of developing HLTV-1-associated myelopathy and adult T-cell
lymphoma/leukemia.87–89,106,107
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In the tropics,measles is associatedwithanannualmortality rate
greater than any other viral disease except HIV.3,9,108,109 Measles
infection produces life-threatening complications among immuno-
compromised hosts including transplant recipients.3,9,108–110 In
addition to acute encephalitis and subacute sclerosing panence-
phalitis in immunocompetent hosts including transplant recipients,
measles virus can causemeasles inclusion body encephalitis.108–110
Vaccination is the main preventive strategy for measles
infection.8,12,110 Antibody titers wane as the degree of immuno-
suppression increases in transplant patients108,109 and prior
vaccination does not guarantee protection in those traveling to
measles endemic areas. Therefore, travel health recommendations
for transplant recipients should take into account rates of measles
in the destination, since measles vaccination is generally contra-
indicated following organ transplantation.8,12,110
3.1.3. Dengue and transplantation
Dengue is an acute viral infection caused by four dengue virus
serotypes and the clinical spectrum ranges from asymptomatic
infection through dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS).90–92 Dengue is considered an emerging
global threat in many tropical and subtropical areas and is
presently endemic in 112 countries.90,91
Immunosuppressed renal transplant recipients with dimin-
ished T-cell responses are at a low risk for DHF and this perhaps
accounts for the lack of clinical reports in such patients.90–92
A recently published case series described 26 cases of dengue fever
(DF) and one case of DHF in renal transplant recipients in Brazil,
demonstrating that dengue infection followed a benign clinical
course with no evidence of long-term damage or precipitation of
acute rejection episodes.91 Interestingly, there is a report of dengue
transmitted through a bone marrow transplant in Puerto Rico
during the dengue epidemics of 1994–1995.92 The donor devel-
oped fever and headache two days after themarrowwas harvested
and tested positive for anti-dengue IgM (DEN-4). The same dengue
virus 4 was isolated from blood, ascitic ﬂuid, and postmortem
tissue samples of the bone marrow recipient.
3.2. Bacterial tropical infections and transplantation
3.2.1. Leprosy and transplantation
Cases ofmycobacterial disease in transplant recipients including
tuberculosis and atypical environmentalMycobacterium have been
described in tropical and non-tropical settings.111–117 In addition,
cases of leprosy in conjunctionwith renal transplantation have been
reported ingeographicareaswhere leprosy ishighlyendemic.118–121
Many hosts were infected prior to transplantation, some were
newly-diagnosedduringtransplant, and three relapsedbetweenone
and three years post-transplantation.118,119 The exact incidence of
leprosy in the transplant population is unknown. In addition, case
reports of leprosy after heart transplant are usually identiﬁed after
episodes of rejection.118,120 Leprosy has also been associated with
bone marrow and human leukocyte antigen (HLA)-identical
allogeneic stem cell transplantation.118 Since the clinicalmanifesta-
tions of leprosy are a result of a complex interaction between
Mycobacterium leprae antigens and the host global immune
response, this infection may potentially alter the clinical presenta-
tion of leprosy in patients with transplantation-associated immu-
nosuppression.118–121 However, there is no compelling evidence yet
that there is a clear alteration of the natural history of the disease,
except for predominance toward the lepromatous end of the
spectrum.118–121 Treatment of leprosy and tuberculosis in solid-
organ and hematopoietic stem cell transplants requires particular
attention todrug interactions; frequently standard regimensneed to
be modiﬁed to prevent drug interactions or side effects.119–1213.2.2. Melioidosis and transplantation
Melioidosis is a serious disease caused by the aerobic Gram-
negative soil-dwelling bacillus Burkholderia pseudomallei and is
most common in Southeast Asia and also in some parts of Latin
America.122,123 Melioidosis often affects individuals with one or
more pre-existing conditions associated with an altered immune
response, the most common being diabetes mellitus (50% of
cases).123 The most severe clinical manifestation is septic shock,
which is often associated with pneumonia and bacterial dissemina-
tion to distant sites. There are isolated reports of this infection
occurring in diabetic renal transplant recipients.124 In this popula-
tion, melioidosis can occur due to primary infection or due to
recrudescence from a latent focus.122,123 It is possible that in some
transplant patientswith a latent focus ofmelioidosis, recrudescence
is preventedby the frequentuseof trimethoprim–sulfamethoxazole
prophylaxis forPneumocystis jirovecipneumonia (PCP) in theﬁrst six
months post-transplantation. It is well known that relapses occur in
10% of cases ofmelioidosis in non-transplant populationswith poor
adherence to eradication therapy, which is usually recommended
for approximately three months.122,123 In transplant recipients
presenting with fever of unknown origin after travel to endemic
regions or living in endemic areas, infection due to B. pseudomallei
needs to be included in the differential diagnosis.122,123
3.2.3. Brucellosis and transplantation
Brucellosis is an intracellular bacterial infection caused by four
major species – Brucella abortus, Brucella melitensis, Brucella suis,
and Brucella canis – usually contracted by consuming raw milk,
unpasteurized dairy products, or by contact with infected
animals.3,124 A case of B. melitensis arthritis in a renal transplant
recipient from Iran has been reported.124 Only two other cases of
brucellosis after transplantation have been published, one with
endocarditis and the other presenting with neurobrucellosis.125
3.2.4. Leptospirosis and transplantation
Leptospirosis is a zoonotic disease caused by the spirochete
Leptospira interrogans with a worldwide distribution, but more
commonly identiﬁed in the tropics and subtropics.3,126,127 There are
30 serogroups of Leptospira spp and approximately 240 sero-
types.3,127 Many mammals, particularly rodents, are reservoirs.
There are two reports of kidney transplant recipientswhodeveloped
leptospirosis with acute renal failure, rhabdomyolysis, and hyper-
bilirubinemia, occurring within two years post-transplantation.
Both recovered successfully with medical therapy.126,127
3.3. Tropical fungal infections
Although there is a limited number of reports of fungal tropical
infections occurring in transplant recipients, they deserve discus-
sion, as the number of transplants in tropical settings and travel to
areas endemic for some fungal infections is increasing, such as for
histoplasmosis, blastomycosis, and coccidioidomycosis.128,129 In
this regard, two increasingly frequent fungal tropical infections
include paracoccidioidomycosis in Latin America and penicillosis
in Southeast Asia.130–132
3.3.1. Paracoccidioidomycosis and transplantation
Paracoccidioidomycosis is the most frequently identiﬁed deep
mycosis in South America.130,131 Paracoccidioidomycosis is rarely
reported in solid-organ transplant patients, and was ﬁrst reported
in 1984 with only a fewmore cases reported since.131 Therefore, it
appears that paracoccidioidomycosis, along with blastomycosis,
are the least common of the endemic mycoses in transplant
recipients.131 The clinical manifestations were likely due to
reactivation of a quiescent latent lesion similar to the non-
transplant otherwise immunocompetent population.130
Table 1
Overall screening recommendations for tropical infections in transplant donors/recipients
Comprehensive medical history, history of travel, residence, occupation, animal exposure is critical to have a suspicion of latent or active tropical infectious diseasesa
Laboratory values (eosinophilia, elevated liver enzymes, and other parameters) can help to assess the risk for latent or active tropical parasitic, viral, bacterial, or
fungal infections
Indications of screening for strongyloidiasis and schistosomiasis in donors and recipients should be based on having a history of travel or residence in an endemic
area; having a history of eosinophilia or a history of unexplained gastrointestinal symptoms
Screening for Trypanosoma cruzi infection should be based on having a history of travel or residence in an endemic area, or having cardiac or gastrointestinal
symptoms that may suggest Chagas disease
Serologic testing for viral infections, particularly HTLV-1 and dengue, should be considered when there is a clinical suspicion or if the patient has resided in a highly
endemic area
Blood cultures, peripheral blood smears (T. cruzi infection, malaria), cultures of respiratory specimens (penicillinosis), serologic testing (strongyloidiasis or
schistosomiasis), and biopsies of lymph nodes (paracoccidioidomycosis) or affected tissues (free-living pathogenic amoebas) may be useful for diagnosis of
tropical infections in transplant recipients depending on clinical history and previous epidemiologic exposures
a Some of these are for screening for elective organ transplantation and some should be considered as diagnostic testing for those who have received transplantation and
who may be suffering from a tropical infectious disease.
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Although P.marneffei infection is rare outside the endemic zones,
isolated cases have been reported in those who have traveled to
these areas. P. marneffei is a fungal opportunistic infection endemic
to Southeast Asia and other tropical and subtropical areas of the
world.8,110,132 Human infection with P. marneffei has been reported
mostly in personswith defects in cellular immunity, those receiving
steroids or immunosuppressive therapy, and more recently HIV-
infected patients. P. marneffei infection has manifested with fever,
pneumonia, and mesenteric lymphadenopathy, but without the
classic skin lesions, in a patient with a cadaveric kidney who had
traveled to an endemic area.8,132 This diagnosis must be considered
for all febrile kidney transplant recipients who have the relevant
clinical and travel history. Besides a fungal infection, other
important differential diagnoses in transplant recipients presenting
with mesenteric lymphadenopathy include tuberculosis and post-
transplant lymphoproliferative disease.8,110,132
4. Recipient and donor screening for tropical infections
Given the urgency of non-elective transplantation protocols
once an organ donor has been identiﬁed, screening the donor for
multiple diseases is often logistically difﬁcult and therefore having
a low threshold for some of the above discussed tropical infections
is critical among those transplant recipients with different clinical
syndromes.8,110,133,134 The potential for infectious disease trans-
mission from a donor to a transplant recipient as the cause of
illness may not be initially considered in the clinical evaluation.
Persistent fever without an etiology, atypical neurological,
gastrointestinal, or pulmonary presentations should alert clinicians
to the possibility of the potential for some tropical infectiousdisease
transmission from a donor to a transplant recipient as the cause of
illness. Investigation of potential donor-transmitted infections
requires communication among physicians inmultiple transplanta-
tion centers, public health authorities, and organ procurement and
transplantationnetworks.94,101,104 In thismanner,emerging tropical
viral, parasitic, bacterial, and fungal pathogens have been identiﬁed
and traced back to donors.6,22,94,101,104
In the caseof electiveorgan transplantations fromrelateddonors,
these offer the advantage of allowing the performance of more
detailed screening protocols.133 Therefore, in this kind of trans-
plantation, obtaining a comprehensive medical history, history of
travel, residence, occupation, or history of abnormal laboratory
values (eosinophilia, elevated liver enzymes, and other parameters)
can help to assess the risk for latent or active tropical parasitic, viral,
bacterial, or fungal infections (Table 1). The vast majority of those
with tropical infections may remain latent and asymptomatic.4
Unexplained eosinophilia in donors and future recipients of solid-
organ and hematopoietic transplants should prompt an evaluation
for occult parasitic infection, including strongyloidiasis and
schistosomiasis.8,110,135 Serologic testing with the Falcon assayand screening test ELISA and enzyme immunoassay (EIA) are the
most sensitive methods for diagnosing schistosomiasis and
strongyloidiasis, respectively.35,135 Indications for screening for
strongyloidiasis in donors and recipients should be based on having
ahistoryof travel or residence in anendemic areaorhavingahistory
of eosinophilia or a history of unexplained gastrointestinal
symptoms. After treatment of a transplant recipient with ivermec-
tin, continuous screening of serological parameters, degree of
eosinophilia, and stool studies are recommended.8,110 The best
conﬁrmatory test for Chagas disease infection is serological
screening with at least two different kinds of serologic assays.22
In the same manner, serologic testing for viral infections,
particularly measles, HTLV-1, and dengue are useful in this setting.
Blood cultures, cultures of respiratory specimens, serologic testing,
and biopsies of lymph nodes may be useful for diagnosing most
tropical fungal infections in transplant recipients.
5. Summary
Nowadays, with the growing pool of transplant survivors in
many areas of the world and increasing migration dynamics,
clinicians need to have a lower clinical suspicion for tropical
infectious diseases appearing in this population. In addition,
transplant recipients traveling to the tropics should undergo
expert pretravel consultation to evaluate the feasibility of travel
and optimize preventive strategies to decrease the risk of acquiring
tropical infections.134 Preventive strategies should also consider
expanding the already existing screening programs in donors and
recipients of solid-organ and hematopoietic stem cells transplants,
to include screening for the most epidemiologically relevant latent
tropical infections.
Conﬂict of interest: No conﬂict of interest to declare.
Financial support: Global Health Institute Emory University.
References
1. Walker M, Zunt JR. Parasitic central nervous system infections in immuno-
compromised hosts. Clin Infect Dis 2005;40:1005–15.
2. Walker M, Kublin JG, Zunt JR. Parasitic central nervous system infections in
immunocompromised hosts: malaria, microsporidiasis, leishmaniasis, and
African trypanosomiasis. Clin Infect Dis 2006;42:115–25.
3. Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant
recipients. Clin Infect Dis 2007;44:857–66.
4. Barsoum RS. Parasitic infections in transplant recipients. Nat Clin Pract Nephrol
2006;2:490–501.
5. Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after
solid organ transplantation. Am J Transplant 2005;5:8–14.
6. Centers for Disease Control and Prevention (CDC). Chagas after organ transplan-
tation—United States, 2001. MMWR Morb Mortal Wkly Rep 2002;51:210–2.
7. Martin-Davila P, Fortun J, Lopez-Vidal R, Norman F, Montes de Oca M,
Zamarron P, et al. Transmission of tropical and geographically restricted
infections during solid-organ transplantation. Clin Microb Rev 2008;21:60–96.
8. McCarthy AE, Mileno MD. Prevention and treatment of travel-related infec-
tions in compromised hosts. Curr Opin Infect Dis 2006;19:450–5.
9. Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases.
I. Protozoal pathogens. Clin Infect Dis 2007;45:1214–20.
C. Franco-Paredes et al. / International Journal of Infectious Diseases 14 (2010) e189–e196 e19510. Jha V, Chugh KS. Posttransplant infections in the tropical countries. Artiﬁcial
Organs 2002;26:770–7.
11. Canales MT, Kasiske BL, Rosenberg ME. Transplant tourism: outcomes of
United States residents who undergo kidney transplantation overseas. Trans-
plant 2006;82:1658–61.
12. Hill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE, et al.
The practice of travel medicine: guidelines by the Infectious Diseases Society
of America. Clin Infect Dis 2006;43:1499–539.
13. Boggild AK, Sano M, Humar A, Salit A, Gilman M, Kain KC. Traveling patterns
and risk behavior in solid organ transplant recipients. J Travel Med 2004;11:
37–43.
14. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of
orthotopic liver transplantation. Liver Transplant 2003;9:451–62.
15. Centers for Disease Control and Prevention (CDC). Blood donor screening for
Chagas disease—United States 2006-2007. MMWR Morb Mortal Wkly Rep
2007; 56:141-3.
16. Riarte A, Luna C, Sabatiello R, Sinagra A, Schiavelli R, De Rissio A, et al. Chagas’
disease in patients with kidney transplants: 7 years of experience, 1989–1996.
Clin Infect Dis 1999;29:561–7.
17. Shokeir AA. Renal transplantation: the impact of schistosomiasis. BJU Int
2001;88:915–20.
18. D’Albuquerque LA, Gonzalez AM, Filho HL, Copstein JL, Larrea FI, Mansero JM,
et al. Liver transplantation from deceased donors serologically positive for
Chagas disease. Am J Transplant 2007;7:680–4.
19. Valar C, Keitel E, Dal Pra D, Gnatta AF, Santos PD, Bianco TC, et al. Parasitic
infection in renal transplant recipients. Transplant Proceed 2007;39:460–2.
20. Bramstedt KA, Xu J. Checklist: passport, plane ticket, organ transplant. Am J
Transplant 2007;7:1698–701.
21. Kennedy SE, Shen Y, Charlesworth JA, Mackie JD, Mahony JD, Kelly JJ, et al.
Outcomes of overseas commercial kidney transplantation: an Australian
perspective. Med J Aust 2005;182:224–7.
22. Centers for Disease Control and Prevention (CDC). Chagas disease after organ
transplantation—Los Angeles, California, 2006. MMWRMorbMortalWkly Rep
2006;55:798–800.
23. Handford EJ, Zhan FB, Lu Y, Giordano A. Chagas disease in Texas: recognizing
the signiﬁcance and implications of evidence in the literature. Soc Sci Med
2007;65:60–79.
24. Hall CS, Fields K. Cutaneous presentation of Chagas’ disease reactivation in a
heart-transplant patient in Utah. J Am Acad Dermatol 2008;58:529–30.
25. Nuesch R, Zimmerli L, Stockli R, Gyr N, Hatz CF. Imported strongyloidiasis: a
longitudinal analysis of 31 cases. J Trav Med 2005;12:80–4.
26. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microb
Rev 2005;18:12–29.
27. Franco-Paredes C. American trypanosomiasis. Chagas disease. In: Kozarsky P,
Arguin P, Reed C, editors. Yellow book: health information for travelers 2007-
2008. Centers for Disease Control and Prevention. London: Elsevier; 2008.
28. Schaeffer MW, Buell JF, Gupta M, Conway GD, Akhter SA, Wagoner LE.
Strongyloides hyperinfection syndrome after heart transplantation. J Heart
Lung Transplant 2004;23:905–11.
29. Said T, Namppory MP, Nair MA, Halim SA, Shetty AV, Kumar E, et al. Hyper-
infection strongyloidiasis: an anticipated outbreak in kidney transplant reci-
pients in Kuwait. Transplant Proc 2007;39:1014–5.
30. Koﬁdis T, Pethig K, Ru¨ther G, Simon AR, Strueber M, Leyh R, et al. Traveling
after heart transplantation. Clin Transplant 2002;16:280–4.
31. Orenstein JM, Russo P, Didier ES, Bowers C, Bunin N, Teachey DT. Fatal
pulmonary microsporidiosis due to encephalitozoon cuniculi following
allogeneic bone marrow transplantation for acute myelogenous leukemia.
Ultrastruct Pathol 2005;29:269–76.
32. Agteresch HJ, van’t Veer MB, Cornelissen JJ, Sluiters JF. Visceral leishmaniasis
after allogeneic hematopoietic stem cell transplantation. Bone Marrow Trans-
plant 2007;40:391–3.
33. Basset D, Faraut F, Marty P, Dereure J, Rosenthal E, Mary C, et al. Visceral
leishmaniasis in organ transplant recipients: 11 new cases and a review of the
literature. Microb Infect 2005;7:1370–5.
34. Carlson JR, Li L, Helton CL, Munn RJ, Wasson K, Perez RV, et al. Disseminated
microsporidiosis in a pancreas/kidney transplant recipient. Arch Pathol Lab
Med 2004;128:e41–3.
35. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect
Dis 2001;33:1040–7.
36. Boulware DR, Stauffer WM, Hendel-Paterson BR, Lopes Rocha JL, Seet RC,
Summer AP, et al. Maltreatment of Strongyloides infection: case series and
worldwide physicians-in-training survey. Am J Med 2007;120:545–51.
37. Franco-Paredes C, Rouphael N, Rodrı´guez-Morales A, Folch E, Mendez N, Hurst
JW. Cardiac manifestations of parasitic diseases part 2. Myocardial manifesta-
tions of parasitic diseases. Clin Cardiol 2007;30:218–22.
38. Xia D, Yan LN, Li B, Zeng Y, Cheng NS, Wen TF, et al. Orthotopic liver
transplantation for incurable alveolar echinococcosis: report of ﬁve cases
from West China. Transplant Proc 2005;37:2181–4.
39. FiorelliAI, StolfNA,HonoratoR,BocchiE,BacalF,UipD,etal. Later evolutionafter
cardiac transplantation in Chagas’ disease. Transplant Proc 2005;37: 2793–8.
40. Phan BA, Laﬂamme MA, Stempien-Otero A, Limaye AP, Buckner FS, Levy WC.
Conﬁrmation of Chagas’ cardiomyopathy following cardiac transplantation.
Heart Vessels 2006;21:325–7.
41. Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation
for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg 2001;71:
1833–8.42. Hoare M, Gelson WT, Antoun N, Alexander GJ. Early recurrence of neurocysti-
cercosis after orthotopic liver transplant. Liver Transplant 2006;12:490–1.
43. Tarr PE, Miele PS, Peregoy KS, SmithMA, Neva FA, Lucey DR. Case report: rectal
administration of ivermectin to a patient with Strongyloides hyperinfection
syndrome. Am J Trop Med Hyg 2003;68:453–5.
44. Barra Valencia V, Moreno Elola-Olaso A, Fundora Suarez JC, Meneu Diaz SF,
Jimenez de los Galanes B, Perez Saborido R, et al. Second case of neurocys-
ticercosis in a patient with liver transplantation (ﬁrst case in Spain): a case
report. Transplant Proc 2007;39:2454–7.
45. Didier ES, Weiss LM. Microsporidiosis: current status. Curr Opin Infect Dis
2006;19:485–92.
46. Udgiri N, Minza M, Kashyap R, Heer M, Gupta CS, Mohandas K, et al. Intestinal
cryptosporidiosis in living related renal transplant recipients. Transplant Proc
2004;36:2128–9.
47. Orenstein JM. Diagnostic pathology of microsporidiosis. Ultrastruct Pathol
2003;27:141–9.
48. Chen XM, Keithly JS, Paya CV, LaRusso N. Cryptosporidiasis. N Engl J Med
2002;340:1723–31.
49. Vaessen N, Verweij JJ, Spijkerman JB, van Hoek B, van Lieshout L. Fatal
disseminated toxoplasmosis after liver transplantation: improved and early
diagnosis by PCR. Netherlands J Med 2007;65:222–3.
50. Sakhuja V, Sud K, Prakash Kalra O, D’Cruz S, Singh Kohli H, Jha V, et al. Central
nervous system complications in renal transplant recipients in a tropical
environment. J Neurolog Sci 2001;183:89–93.
51. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised
population. Clin Microbiol Rev 2004;17:208–17.
52. Matsuzawa K, Nakamura F, Abe M, Okamoto K. Immunosuppressive and
antiparasitic effects of cyclosporine A on Hymenolepis nana infection in mice.
Int J Parasitol 1998;28:379.
53. Schad GA. Cyclosporine may eliminate the threat of overwhelming strongy-
loidiasis in immunosuppressed patients. J Infect Dis 1986;153:178.
54. Gupta RK, Jain M. Renal transplantation: potential source of microﬁlarial
transmission. Transplant Proc 1998;30:4320–1.
55. Pungpapong S, Krishna M, Abraham SC, Keaveny AP, Dickson RC, Nakhleh RE.
Clinicopathologic ﬁndings and outcomes of liver transplantation using grafts
from donors with unrecognized and unusual diseases. Liver Transplant
2006;12:310–5.
56. Gallerano V, Consigli J, Pereyra S, Gomez Zanni S, Danielo C, Gallerano RH, et al.
Chagas’ disease reactivation with skin symptoms in a patient with kidney
transplant. Int J Dermatol 2007;46:607–10.
57. Amato JG, Amato Neto V, Amato VS, Duarte MI, Uip DE, Boulos M. Cutaneous
lesions as the only manifestations of reactions to Trypanosoma cruzi infection
in a recipient of a kidney transplant. Rev Soc Bras Med Trop 1996;30:61–3.
58. Leiby DA, Herron Jr RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los
Angeles and Miami blood donors: impact of evolving donor demographic on
seroprevalence and implications for transfusion transmission. Transfusion
2002;42:459–65.
59. Nowicki MJ, Chinchilla C, Corado L, Matsuoka L, Selby R, Steurer F, et al.
Prevalence of antibodies to Trypanosoma cruzi among solid organ donors in
Southern California: a population at risk. Transplantation 2006;81:477–9.
60. Tobler LH, Contestable P, Pitina L, Groth H, Shaffer S, Blackburn GR, et al.
Evaluation of a new enzyme-linked immunosorbent assay for detection of
Chagas antibody in US blood donors. Transfusion 2007;47:90–6.
61. Leiby DA, Herron Jr RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los
Angeles and Miami blood donors: impact of evolving donor demographics on
seroprevalence and implications for transfusion transmission. Transfusion
2002;42:549–55.
62. Arias LF, Duque E, Ocampo C, Henao J, Zuluaga G, Varela G, et al. Detection of
amastigotes of Trypanosoma cruzi in a kidney graft with acute dysfunction.
Transplant Proc 2006;38:885–7.
63. DictarM, SinagraA, Vero´nMT, LunaC,Dengra C,DeRissio A, et al. Recipients and
donorsofbonemarrowtransplantssuffering fromChagas’disease:management
andpreemptivetherapyofparasitemia.BoneMarrow Transplant 1998;21:391–3.
64. Souza AA, Lobo MC, Barbosa RA, Bello V. Chagas seropositive donors in kidney
transplantation. Transplant Proc 2004;36:868–9.
65. Vazquez MC, Sabbatiello R, Schiavelli R, Maiolo E, Jacob N, Pattin M, et al.
Chagas disease and transplantation. Transplant Proc 1996;28:3301–3.
66. Altclas J, Sinagra A, Dictar M, Luna C, Vero´n MT, De Rissio AM, et al.
Reactivation of chronic Chagas’ disease following allogeneic bone marrow
transplantation and successful pre-emptive therapy with benznidazole.
Transpl Infect Dis 1999;1:135–7.
67. Mejia GA, Alvarez CA, Pulido HH, Ramirez B, Cardozo C, Suarez Y, et al. Malaria
in a liver transplant recipient: a case report. Transplant Proc 2006;38:3132–4.
68. Arslan H, Inci EK, Azap OK, Karakayali H, Torgay A, Haberal M. Etiologic agent
of diarrhea in solid organ recipients. Transpl Infect Dis 2007;9:270–5.
69. Bennett WM, Nespral JF, Rosson MW, McEvoy KM. Use of organs for trans-
plantation from a donor with primary meningoencephalitis due to Naegleria
fowleri. Am J Transplant 2008;8(6):1334–5.
70. Barete S. Fatal disseminated Acanthamoeba lenticulata infection in a heart
transplant. Emerg Infect Dis 2007;13:736–8.
71. Duarte AG, Sattar F, Granwher B, Aronson JF, Wang Z, Lick S. Disseminated
acanthamoebiasis after lung transplantation. J Heart Lung Transplant 2006;25:
237–40.
72. Steinberg JP, Galindo RL, Kraus ES, Ghanem KG. Disseminated acanthamoe-
biasis in a renal transplant recipientwith osteomyelitis and cutaneous lesions:
case report and review of the literature. Clin Infect Dis 2002;35:e43–9.
C. Franco-Paredes et al. / International Journal of Infectious Diseases 14 (2010) e189–e196e19673. Anderlini P, Przepiorka D, Luna M, Langford L, Andreeff M, Claxton D, et al.
Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone
Marrow Transplant 1994;14:459–61.
74. Vernon SE, Acar BC, Pham SM, Fertel D. Acanthamoeba infection in lung
transplantation: report of a case and review of the literature. Transplant Infect
Dis 2005;7:154–7.
75. Peleg AY, Husain S, Kwak EJ, Silveira FP, Magdaline N, Tran J, et al. Opportu-
nistic infections in 547 organ transplant recipients receiving alemtuzumab, a
humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44:204–12.
76. Kramer MH, Lerner CJ, Visvesvara GS. Kidney and liver transplants from a
donor infected with Naegleria fowleri. J Clin Microbiol 1997;35:1032–3.
77. HoareM, GelsonWT, Davies SE, CurranM, Alexander GJ. Hepatic and intestinal
schistosomiasis after orthotopic liver transplant. Liver Transplant 2005;11:
1603–7.
78. Pannegeon V, Masini JP, Paye F, Chazouilleres O, Girard PM. Schistosoma
mansoni infection and liver graft. Transplantation 2005;80:287.
79. Mudawi HM, Elhassan AM, Baraka OZ, El Hassan A. Schistosomal colitis
without granuloma formation in a kidney transplant recipient. Nature Clin
Pract Gastroenterol Hepatol 2006;3:700–4.
80. Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, et al. Schistoso-
miasis. N Engl J Med 2002;346:1212–8.
81. Vinhal FA, Afonso-Cardoso SR, Silva AG, Pereira CG, SousaW, Botelho SM, et al.
Atypical presentation of cutaneous leishmaniasis after renal transplantation.
Nephrol Dial Transplant 2007;22(12):3674.
82. Mirzabeigi M, Farooq U, Baraniak S, Dowdy L, Ciancio G, Vincek V. Reactivation
of dormant cutaneous Leishmania infection in a kidney transplant recipient.
J Cutan Pathol 2006;33:701–4.
83. Clemente WT, Alves Couto C, Dias Ribeiro D, Chaves Franca MM, Dias Sanches
M. An atypical course of visceral leishmaniasis (kala-azar) in a liver transplant
recipient. Transplant 2007;83:368–9.
84. Rajcani J. Reactivation of latent DNA viruses during immunosuppression: basic
contemplation. Acta Virol 2007;51:77–100.
85. Freeman AF, Jacobsohn DA, Shulman ST, Bellini WJ, Jaggi P, de Leon G, et al.
A new complication of stem cell transplantation: measles inclusion body
encephalitis. Pediatrics 2004;114:e657–60.
86. Machado CM, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early
measles vaccination in bone marrow transplant recipients. Bone Marrow
Transplant 2005;35:787–91.
87. Verdnock K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E.
Human T-lymphotropic virus 1: recent knowledge about an ancient infection.
Lancet Infect Dis 2007;7:266–81.
88. Nakatsuji Y, Sugai F, Watanabe S, Kaido M, Koguchi K, Abe K, et al. HTLV-1
associated myelopathy manifested after renal transplantation. J Neurol Sci
2000;177:154–6.
89. Osman HK. Human T-cell lymphotropic virus type 1: is it time to screen organ
donors and recipients? Transplant 2003;75:1–2.
90. Chacko B, John GT, Jacob CK, Vijayakumar TS. Dengue shock syndrome in a
renal transplant recipient. Transplant 2004;77:634–9.
91. Azevedo LS, Carvalho DB, Matuck T, Alvarenga MF, Morgado L, Magalhaes I,
et al. Dengue in renal transplant patients: a retrospective analysis. Transplant
2007;84:792–4.
92. Rigau-Perez JG, VorndamV, Clark GG. The dengue and dengue hemorrhagic
fever epidemic in Puerto Rico. Am J Trop Med Hyg 2001;64:67–74.
93. Ivanovski N, Stojkovski L, Cakalaroski K, Masin G, Djikova S, Polenakovic M.
Renal transplantation from paid, unrelated donors— it is not only unethical, it
is medically unsafe. Nephrol Dial Transplant 1997;12:2028.
94. IwamotoM, Jernigan J, Guasch A, TrepkaMJ, Blackmore CG, HellingerWC, et al.
Transmission of West Nile virus from organ donor to four transplant recipi-
ents. N Engl J Med 2003;348:2196–203.
95. Jain N, Fisk D, Sotir M, Kehl KS. West Nile virus encephalitis, status epilepticus
and West Nile pneumonia in a renal transplant patient. Transplant Int
2007;20:800–3.
96. Komar N, Clark GG. West Nile virus activity in Latin America and the Car-
ibbean. Rev Panam Salud Publica 2006;19:112–7.
97. Ferna´ndez-Salas I, de Lourdes Garza-Rodrı´guez M, Beaty BJ, Jime´nez JR, Rivas-
Estilla AM. Presence of West Nile virus in northeast Mexico. Salud Publica Mex
2007;49:210–7.
98. Berrocal L, Pen˜a J, Gonza´lez M, Mattar S. West Nile virus: ecology and
epidemiology of an emerging pathogen in Colombia. Rev Salud Publica (Bogota)
2006;8:218–28.
99. Morales MA, BarrandeguyM, Fabbri C, Garcia JB, Vissani A, Trono K, et al. West
Nile virus isolation from equines in Argentina, 2006. Emerg Infect Dis 2006;12:
1559–61.
100. Bosch I, Herrera F, Navarro JC, Lentino M, Dupuis A, Maffei J, et al. West Nile
virus, Venezuela. Emerg Infect Dis 2007;13:651–3.
101. Fischer SA, GrahamMB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, et al.
Transmission of lymphocytic choriomeningitis virus by organ transplantation.
N Engl J Med 2006;354:2235–49.
102. Meier M, Helmchen U, Fricke L, Ulrich R, Schutt M. Acute hantavirus infection
or renal transplant rejection. Transpl Infect Dis 2007;9:225–8.
103. Solomon T. Flavivirus encephalitis. N Engl J Med 2004;351:370–8.
104. Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, SutkerWL, Ksizek TG, et al.
Transmission of rabies virus from an organ donor to four transplant recipients.
N Engl J Med 2005;352:1103–11.
105. Wilde H, Briggs DJ, Meslin FX, Hemachudha T, Sitprija V. Rabies update for
travel medicine advisors. Clin Infect Dis 2003;37:96–100.106. Osman HK, Toro C, Rodes B, Poveda E, Soriano V. Rapid development of
subacute myelopathy in three organ transplant recipients after transmission
of human T-cell lymphotropic virus type I from a single donor. Transplant
2003;75:102.
107. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infections risks of
blood transfusions. JAMA 2003;289:959–62.
108. Turner A, Jeyaratnam D, Haworth F, Sinha MD, Hughes E, Cohen B, et al.
Measles-associated encephalopathy in children with renal transplants. Am J
Transplant 2006;6:1459–65.
109. Warmington L, Lee BE, Robinson JL. Loss of antibodies to measles and varicella
following solid organ transplantation in children. Pediatr Transplant 2005;9:
311–4.
110. Suh KN, Milano MS. Challenging scenarios in a travel clinic: advising the
complex traveler. Infect Dis North Am 2005;19:15–47.
111. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ
transplant recipients: impact and implications for management. Clin Infect
Dis 1998;27:1266–77.
112. Gaviria JM, Garcia PJ, Garrido SM, Corey L, Boeckh M. Nontuberculous myco-
bacterial infections in hematopoietic stem cell transplant recipients: char-
acteristics of respiratory and catheter-related infections. Biol Blood Marrow
Transplant 2000;6:361–9.
113. Tebas P, Sultan F, Wallace Jr RJ, Fraser V. Rapid development of resistance
to clarithromycin following monotherapy for disseminated Mycobacterium
chelonae infection in a heart transplant patient. Clin Infect Dis 1995;20:
443–4.
114. Johan GT, den Broeder AA, Vervoort G, van Assen S, Verduyn Lunel F, de Lange
WC, et al. Disseminated Mycobacterium gordonae infection in a renal trans-
plant recipient. Transpl Infect Dis 2003;5:151–5.
115. Fairhurst RM, Kubak BM, Pegues DA, Moriguchi JD, Han KF, Haley JC, et al.
Mycobacterium haemophilum infections in heart transplant recipients: case
report and review of the literature. Am J Transplant 2002;2:476–9.
116. Fairhurst RM, Kubak BM, Shpiner RB, Levine MS, Pegues DA, Ardehali A.
Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung
Transplant 2002;21:391–4.
117. Freudenberger RS, Simafranca SM. Cutaneous infection with rapidly-growing
mycobacterial infection following heart transplant: a case report and review
of the literature. Transplant Proc 2006;38:1526–9.
118. Pieroni F, Stracieri AB, Moraes DA, Paton EJ, Saggioro FP, Barros GM, et al. Six
cases of leprosy associated with allogeneic hematopoietic SCT. Bone Marrow
Transplant 2007;1–5.
119. Launius BK, Brown PA, Cush E, Mancini MC. A case study in Hansen’s disease
acquired after heart transplant. Crit Care Nurs Q 2004;27:87–91.
120. Agarwal DK, Mehta AR, Sharma AP, Sural S, Kumar A, Mehta B, et al. Coin-
fection with leprosy and tuberculosis in a renal transplant recipient. Nephrol
Dial Transplant 2000;15:1720.
121. Gasink LB, Seymour C, Blumberg EA, Goldberg LR, Fishman NO. An uncommon
presentation of an uncommon disease: leprosy in a heart transplant recipient.
J Heart Lung Transplant 2006;25:854–6.
122. John GT, Ahmed I, Jacob CK. Melioidosis in a renal transplant recipient.
Transplant 2003;76:262.
123. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis:
insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microb
2006;4:272–82.
124. Einollahi B, Hamedanizadeh AK, Alavian SM. Brucellosis arthritis—a rare
complication of renal transplantation: a case report. Transplant Proc 2003;
35:2698.
125. Yousif B, Nelson J. Neurobrucellosis—a rare complication of renal transplanta-
tion. Am J Nephrol 2001;21:66–8.
126. Manfro RC, Boger MV, Kopstein J, Gonc¸alves LF, Prompt CA. Acute renal failure
due to leptospirosis in a renal transplant patient. Nephron 1993;64:317.
127. Khosravi M, Bastani B. Acute renal failure due to leptospirosis in a renal
transplant recipient: a brief review of the literature. Transplant Proc
2007;39:1263–6.
128. Serody JS, Mill MR, Detterbeck FC, Harris DT, Cohen MS. Blastomycosis in
transplant recipients: reports of a case and review. Clin Infect Dis 1993;16:
54–8.
129. Young SO, Lisker-Melman M, Korenblat KM, Zuckerman GR, Crippin JS. Dis-
seminated histoplasmosis in a liver transplant recipient. Liver Transplant
2006;12:677–81.
130. Benard G, Duarte AJ. Paracoccidioidomycosis: a model for evaluation of the
effects of human immunodeﬁciency virus infection on the natural history of
pandemic tropical diseases. Clin Infect Dis 2000;31:1032–9.
131. Zavascki AP, Bienardt JC, Severo LC. Paracoccidioidomycosis in organ trans-
plant recipient: case report. Rev Inst Med Trop Sao Paulo 2004;46:279–81.
132. Chan YH, Wong KM, Lee KC, Kwok PC, ChakWL, Choi KS, et al. Pneumonia and
mesenteric lymphadenopathy caused by disseminated Penicillium marneffei
infection in a cadaveric renal transplant recipient. Transpl Infect Dis 2004;6:
28–32.
133. Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect
Dis 2002;35:1513–9.
134. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ
transplant recipients: current recommendations and protocols. Clin Microbiol
Rev 2003;16:357–64.
135. Page WA, Dempsey K, McCarthy JS. Utility of serological follow-up of chronic
strongyloidiasis after anthelminthic chemotherapy. Trans R Soc Trop Med Hyg
2006;100:1056–62.
